| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2021cafa8df7b0dec20ae2c7682f639
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca32fd2a44fd326ffd027a75a57bd13f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1870024223df71c715c62d0edd723acb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate |
2020-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0e018a7e276c2c6194319ed2e6e76a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41bf8e458a8711db1a41dc6bc9879c68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6da7cf0828c18dae8d62f12b018d271b |
| publicationDate |
2021-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021018786-A1 |
| titleOfInvention |
Use of ffar2 agonists for the treatment of bacterial superinfections post-viral infection |
| abstract |
Severe influenza is associated with defects in pulmonary innate immunity, a phenomenon leading to secondary bacterial infections. The gut microbiota can control immune/inflammatory responses locally and at distant sites. The inventors hypothesized that perturbation of the gut microbiota during severe influenza might participate in bacterial superinfection. Their data demonstrated that influenza infection profoundly altered the functionality of the gut microbiota as assessed by the altered production of short chain fatty acids (SCFAs). Remarkably, treatment of IAV-infected mice with acetate, the main SCFA found systematically, reinforced host defenses against S. pneumoniae. Lastly, the inventors showed that pharmacological manipulation of the FFAR2 agonist TUG-1375 provides the same benefit as acetate in the treatment of bacterial superinfection post-influenza. The present invention thus relates to the use of synthetic free fatty acid receptor 2 (FFAR2) agonist for the treatment of bacterial superinfections post-viral infection (e.g. post-influenza). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116421606-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116421606-B |
| priorityDate |
2019-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |